The Expression of Immune Checkpoint Inhibitors PDL-1 and CTLA-4 in Pancreatic Versus Non-Pancreatic Periampullary Adenocarcinoma: An Immunohistochemical Study

Assessment of PD-L1 and p53 expression in urinary bladder carcinoma: Association with different clinicopathologic characteristics

Immunohistochemical expression of programmed death-ligand 1 (PD-L1) in invasive duct carcinoma of the breast of no special type and correlation with patients' clinicopathological parameters

PD-L1 Expression in Colorectal Cancer and Its Relation to Microsatellite Instability and Cytotoxic Tumor-Infiltrating Lymphocytes

CLINICOPATHOLOGICAL SIGNIFICANCE OF PROGRAMED DEATH -LIGAND -1(PD-L1) AND PROLIFERATION CELL NUCLEAR ANTIGE(PCNA)EXPRESSION IN PROSTATIC CARCINOMA; AN IMMUNOHISTOCHEMICAL STUDY"

High expression of the checkpoint molecule PD-1 on conventional CD4+ and regulatory T cells in the peripheral blood of Hepatocellular carcinoma patients

Assessment of PI3KCA immunohistochemical expression and tumor infiltrating lymphocytes (CD4 and CD8) in invasive breast carcinoma and their relation to molecular subtypes

Prognostic Value of Programed Cell Death-1 Ligand Expression in Colorectal Cancer and Its Correlation with Cytotoxic Tumor-Infiltrating Lymphocytes

High expression of the checkpoint molecule PD-1 on regulatory and helper CD4+ T cells in metastatic breast cancer patients with poor prognosis

Expression of programmed death ligand 1 (PD-L1) in urothelial bladder carcinoma (immunohistochemical and histopathological study)